House Compounding Bill Would Regulate “Outsourcing Facilities” With Volume Limits
This article was originally published in The Pink Sheet Daily
Reps. Griffith, DeGette, and Green co-sponsor bill to improve FDA oversight of compounding with some provisions similar to Senate bill, possibly opening door to compromise.
You may also be interested in...
Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.
While many interpretations of the law protecting the first interchangeable biosimilar approved for a reference product are included in a recently released FDA memo, the agency says it has a limited scope.
The current crop of cancer drug approvals were well along in development when Project Optimus launched, meaning they may not have been able to implement the Oncology Center of Excellence’s premarket dose optimization policy.